The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence
Crossref DOI link: https://doi.org/10.1007/s11239-023-02776-z
Published Online: 2023-02-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schiffer, Sonja http://orcid.org/0000-0001-9708-691X
Schwers, Stephan
Heitmeier, Stefan
Text and Data Mining valid from 2023-02-06
Version of Record valid from 2023-02-06
Article History
Accepted: 15 January 2023
First Online: 6 February 2023
Declarations
:
: All authors are employees of Bayer AG.
: Not applicable.